Abingdon Health PLC AppDx(R) granted further patent
March 07 2023 - 2:00AM
RNS Non-Regulatory
TIDMABDX
Abingdon Health PLC
07 March 2023
Abingdon Health plc
("Abingdon Health" or "the Company")
AppDx (R) lateral flow smartphone reader granted further
patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a
leading international lateral flow contract development and
manufacturing organisation (CDMO), announces the granting of an
additional patent for its AppDx (R) lateral flow smartphone
reader.
AppDx (R) is a software development kit (SDK) for reading
colorimetric lateral-flow tests (LFT) organized for Android(TM) and
iOS(R) smartphone operating systems. AppDx (R) enables lateral-flow
test readout from your pocket, enabled by a smartphone camera, that
can be used by any user app. It consists of a software Application
Programming Interface (API) accessed as a library which contains
algorithms for image processing and deep learning in order to read
a lateral-flow test using a smartphone. The algorithms need to be
customized and tuned for each test. The Abingdon Health AppDx (R)
algorithm reads the lateral flow device qualitatively (e.g.
positive/negative) and semi-quantitively (e.g.
negative/high/medium/low). A key point of differentiation is that
the algorithm may be located on the smartphone, therefore not
requiring a Wifi connection or 4G connection. It can also be
provided as a web server-based solution.
The granted patent (GB 2601978) relates to the use of a
plurality of captured images to provide a more refined algorithm
which allows variations in imaging conditions to be averaged out
and/or outliers removed. This allows the algorithm to counteract
typically seen issues with measuring lateral flow devices such as
specks of dust, reflections other artefacts and importantly
different lighting conditions. These are important factors when
considering the use of lateral flow tests in a range of different
environments such as the home, doctor's office, veterinary office,
farm or field. This innovation therefore is of critical importance
in enabling the application of AppDx (R) commercially across a
range of applications.
This is the third patent granted to Abingdon Health in relation
to AppDx (R), including the granting of patent GB 2583419 which
covers the use of neural-network based detection of lateral-flow
tests, extracting the region-of-interest, and processing the data
to calculate the values of the assay lines. This covers the
two-stage pipeline where the assay area is extracted from the
picture and image processing algorithms measure the line values and
positions.
Chris Yates, CEO of Abingdon Health plc, commented: "We are
pleased to announce the granting of a further patent for our AppDx
(R) smartphone lateral flow reader. Given the expected rapid growth
in the lateral flow self-test market we believe the use of
smartphone apps, such as AppDx(R), will be critical in allowing
widespread adoption of lateral flow rapid-testing.
"This patent grant underlines Abingdon's focus on innovation to
support its customers and we now look forward to initiating
commercial discussions to bring this product to market."
Enquiries
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development
and manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an
ecommerce platform that offers a range of self-tests to empowers
consumers to manage their own health and wellbeing. The Abingdon
Simply Test ecommerce site offers consumers a range of information
to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland such
as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUAGWUPWGBQ
(END) Dow Jones Newswires
March 07, 2023 02:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jul 2023 to Jul 2024